1. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma 
Jeff L. Hummel, Ekaterina Safroneeva, Karen L. Mossman 
Molecular Therapy 
Volume 12, Issue 6, Pages (December 2005)
DOI: /j.ymthe
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

2. FIG. 1
(A) In situ cytopathic effects of KM100 in human and murine breast adenocarcinomas. Indicated cells were infected with serum free medium (mock), wild-type HSV-1 (KOS), and the ICP0 mutant KM100 at an m.o.i. of ∼2. Cells were stained 24 h postinfection. (B) Kaplan–Meier survival analysis of FVB mice following intratumoral injection of subcutaneous murine PyMT breast adenocarcinoma explants. Arrows indicate time of injection (2 × 107 pfu per injection).
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

3. FIG. 2
Intergroup comparison of survival data using the log-rank test. Significance was determined as P < 0.05.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

4. FIG. 3
Tumor regression analysis of individual mice within each treatment group. The scale of the y axis is representative of the maximum tumor growth observed. Mice exhibiting tumors that regressed over 50-fold are identified with stars. Tumor regression is shown to the point of complete regression, whereas tumor growth is shown to the point of sacrifice.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

5. FIG. 4
Comparison of tumor regression analyses between (A) single and (B) triple treatment groups. The average fold change in tumor volume per group is represented. Significance using one-way ANOVA followed by Tukey's test was set at P < 0.05. Single dose serum-free medium (single SF) is plotted for comparison purposes.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

6. FIG. 5
Detection of an anti-tumor immune response following KM100 treatment of PyMT tumor explants. (A) Anti-IgG1 serum levels detected by ELISA. (B) Anti-IgG1 serum levels stratified by regression status. (C) Anti-IgG2a serum levels detected by ELISA. (D) Anti-IgG2a serum levels stratified by regression status.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions